Ahead of like­ly ap­proval, ICER finds Geron’s ime­tel­stat is not cost-ef­fec­tive at $250,000 an­nu­al­ly

In the lead-up to the like­ly ap­proval of Geron’s drug to treat cer­tain types of ane­mia, drug pric­ing watch­dog the In­sti­tute for Clin­i­cal and Eco­nom­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.